Hims & Hers debates ‘unresolved’ after earnings, says Morgan Stanley
Morgan Stanley notes that Hims & Hers beat in Q4 and guided Q1 and calendar year 2025 revenue significantly above the Street consensus.
Hims & Hers flags possible halt to compounded weight-loss drug sales; shares slump
Investing.com - Hims&Hers (NYSE:HIMS) said on Monday that it may stop selling legal copies of a popular weight-loss drug made by Denmark's Novo Nordisk (NYSE:NVO), sending shares in the U.S.
Novo shares rise as HIMS halt sales of some obesity drugs
Novo Nordisk shares climbed more than 3% premarket on Tuesday after Hims&Hers Health announced it may no longer sell compounded versions of semaglutide, the active ingredient in Novo’s weight-loss ...
These Stocks Are Moving the Most Today: Super Micro, Nvidia, Home Depot, Palantir, Hims & Hers, MicroStrategy, PayPal, and More
Super Micro has until Tuesday to file delayed financial accounts or risk being delisted by the Nasdaq stock exchange, ...
pharmaphorum33m
Lilly launches discounted Zepbound vials in US
Lilly recently revised its revenue forecast for 2024 after seeing weaker-than-expected growth for Zepbound and diabetes brand ...
pharmaphorum30m
Lilly launches discounted high-strength Zepbound vials in US
Lilly recently revised its revenue forecast for 2024 after seeing weaker-than-expected growth for Zepbound and diabetes brand ...